Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients

NCT02088060 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.

NCT NCT02088060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02088060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients
Lead sponsor
Central Institute of Mental Health, Mannheim
Phase
Phase 2
Overall status
Terminated
Start date
December 8, 2015
Completion date
September 16, 2024
Enrollment
150 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia